CD8A and ovarian cancer: For example, nine administrations of an oncolytic adenovirus, ONCOS‐102, into a patient with chemotherapy‐refractory ovarian cancer in a phase I trial induced and progressively enhanced CD8+ infiltration in the treated tumor lesions.15